Go to
JCI Insight
Citations to this article
Muriel Aguilar-Bretones, … , Marion P.G. Koopmans, Gijsbert P. van Nierop
Published September 9, 2021
Citation Information: J Clin Invest. 2021;131(21):e150613. https://doi.org/10.1172/JCI150613.
Citation Information: J Clin Invest. 2021;131(21):e150613. https://doi.org/10.1172/JCI150613.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Little is known about the interplay between preexisting immunity to endemic seasonal coronaviruses and the development of a SARS-CoV-2–specific IgG response. We investigated the kinetics, breadth, magnitude, and level of cross-reactivity of IgG antibodies against SARS-CoV-2 and heterologous seasonal and epidemic coronaviruses at the clonal level in patients with mild or severe COVID-19 as well as in disease control patients. We assessed antibody reactivity to nucleocapsid and spike antigens and correlated this IgG response to SARS-CoV-2 neutralization. Patients with COVID-19 mounted a mostly type-specific SARS-CoV-2 response. Additionally, IgG clones directed against a seasonal coronavirus were boosted in patients with severe COVID-19. These boosted clones showed limited cross-reactivity and did not neutralize SARS-CoV-2. These findings indicate a boost of poorly protective CoV-specific antibodies in patients with COVID-19 that correlated with disease severity, revealing “original antigenic sin.”
Authors
Muriel Aguilar-Bretones, Brenda M. Westerhuis, Matthijs P. Raadsen, Erwin de Bruin, Felicity D. Chandler, Nisreen M.A. Okba, Bart L. Haagmans, Thomas Langerak, Henrik Endeman, Johannes P.C. van den Akker, Diederik A.M.P.J. Gommers, Eric C.M. van Gorp, Corine H. GeurtsvanKessel, Rory D. de Vries, Ron A.M. Fouchier, Barry H.G. Rockx, Marion P.G. Koopmans, Gijsbert P. van Nierop
Citation information
Citations to this article (45)
| Title and authors | Publication | Year |
|---|---|---|
|
A Call for Action: Lessons Learned From a Pilot to Share a Complex, Linked COVID-19 Cohort Dataset for Open Science
Amid C, van Roode MY, Rinck G, van Beek J, de Vries RD, van Nierop GP, van Gorp EC, Tobian F, Oude Munnink BB, Sikkema RS, Jaenisch T, Cochrane G, Koopmans MP |
JMIR Public Health and Surveillance | 2025 |
|
In-depth immunochemical characterization of the serum antibody response using a dual-titration microspot assay
Kovács Á, Hérincs Z, Papp K, Kaczmarek JZ, Larsen DN, Stage P, Bereczki L, Ujhelyi E, Pfeil T, Prechl J |
Frontiers in Immunology | 2025 |
|
Distinct immune responses in people living with HIV following SARS-CoV-2 recovery
Mielke D, Li SS, Schuster DJ, Li X, Hu J, Karuna S, Seaton KE, Brackett C, Dunn B, Keyes T, Zalaquett A, Stanfield-Oakley S, Zhang L, Wesley MS, Eisel N, Yates NL, Shen X, Premkumar L, Germain RS, Sholukh AM, Cohen K, de Rosa S, Randhawa AK, Hural JA, Corey L, McElrath MJ, Tomaras GD, Hyrien O, Ferrari G |
Communications Medicine | 2025 |
|
Use of immunology in news and YouTube videos in the context of COVID-19: politicisation and information bubbles
George RS, Goodey H, Russo MA, Tula R, Ghezzi P |
Frontiers in public health | 2024 |
|
The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects
Collins CP, Longo DL, Murphy WJ |
Frontiers in immunology | 2024 |
|
Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin.
Pušnik J, Zorn J, Monzon-Posadas WO, Peters K, Osypchuk E, Blaschke S, Streeck H |
Nature Communications | 2024 |
|
SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity.
Aguilar-Bretones M, den Hartog Y, van Dijk LLA, Malahe SRK, Dieterich M, Mora HT, Mueller YM, Koopmans MPG, Reinders MEJ, Baan CC, van Nierop GP, de Vries RD |
npj Vaccines | 2024 |
|
Reduced seasonal coronavirus incidence in high‐risk population groups during the COVID‐19 pandemic
Heiskanen A, Galipeau Y, Little J, Langlois M, Cooper CL |
Immunity, Inflammation and Disease | 2024 |
|
Immune imprinting: The persisting influence of the first antigenic encounter with rapidly evolving viruses.
Maltseva M, Keeshan A, Cooper C, Langlois MA |
Human vaccines & immunotherapeutics | 2024 |
|
Recent Endemic Coronavirus Infection Associates With Higher SARS-CoV-2 Cross-Reactive Fc Receptor Binding Antibodies
Bean DJ, Liang YM, Sagar M |
bioRxiv | 2024 |
|
Impact of antigenic drift and original antigenic sin on SARS-CoV-2 immunity
Muriel Aguilar-Bretones1, Ron A.M. Fouchier1, Marion P.G. Koopmans1 and Gijsbert P. van Nierop1† |
Journal of Clinical Investigation | 2023 |
|
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Zsichla L, Müller V |
Viruses | 2023 |
|
Differential abundance of IgG antibodies against the spike protein of SARS-CoV-2 and seasonal coronaviruses in patients with fatal COVID-19.
Smit WL, van Tol S, Haas LEM, Limonard GJM, Bossink A, Reusken C, Heron M, Thijsen SFT |
Virology Journal | 2023 |
|
Viral persistence, reactivation, and mechanisms of long COVID.
Chen B, Julg B, Mohandas S, Bradfute SB |
eLife | 2023 |
|
Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19
Rümke LW, Smit WL, Bossink A, Limonard GJ, Muilwijk D, Haas LE, Reusken C, van der Wal S, Thio BJ, van Os YM, Gremmels H, Beekman JM, Nijhuis M, Wensing AM, Heron M, Thijsen SF |
Frontiers in immunology | 2023 |
|
Pre-existing Immunity to Endemic Human Coronaviruses Does Not Affect the Immune Response to SARS-CoV-2 Spike in a Murine Vaccination Model
Jeong AY, Lee P, Lee MS, Kim DJ |
Immune Network | 2023 |
|
Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination
Yin D, Han Z, Lang B, Li Y, Mai G, Chen H, Feng L, Chen YQ, Luo H, Xiong Y, Jing L, Du X, Shu Y, Sun C |
Frontiers in immunology | 2023 |
|
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
Raadsen MP, Dahlke C, Fathi A, Lamers MM, van den Doel P, Zaeck LM, van Royen ME, de Bruin E, Sikkema R, Koopmans M, van Gorp EC, Sutter G, de Vries RD, Addo MM, Haagmans BL |
The Journal of Infectious Diseases | 2023 |
|
Individual Immune Response to SARS-CoV-2 Infection—The Role of Seasonal Coronaviruses and Human Leukocyte Antigen
Rottmayer K, Loeffler-Wirth H, Gruenewald T, Doxiadis I, Lehmann C |
Biology | 2023 |
|
Immune imprinting and next-generation coronavirus vaccines.
Huang CQ, Vishwanath S, Carnell GW, Chan ACY, Heeney JL |
Nature Microbiology | 2023 |
|
Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19.
Vasconcelos LCM, Leony LM, Camelier AA, Meireles AC, Oliveira Júnior ALF, Bandeira AC, Macedo YSF, Duarte AO, Van Voorhis W, Siqueira IC, Santos FLN |
2023 | |
|
Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.
Herman JD, Atyeo C, Zur Y, Cook CE, Patel NJ, Vanni KM, Kowalski EN, Qian G, Srivatsan S, Shadick NA, Rao DA, Kellman B, Mann CJ, Lauffenburger D, Wallace ZS, Sparks JA, Alter G |
Science Translational Medicine | 2023 |
|
T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
Lichen Jing, Xia Wu, Maxwell P. Krist, Tien-Ying Hsiang, Victoria Campbell, Christopher McClurkan, Sydney Favors, Lawrence Hemingway, Charmie Godornes, Denise Q Tong, Stacy Selke, Angela LeClair, Chul-Woo Pyo, Daniel E. Geraghty, Kerry J. Laing, Anna Wald, Michael Gale, Jr., David Koelle |
JCI Insight | 2022 |
|
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
Anna L McNaughton, Robert S Paton, Matthew Edmans, Jonathan C W Youngs, Judith Wellens, Prabhjeet Phalora, Alex Fyfe, Sandra Belij-Rammerstorfer, Jai S Bolton, Jonathan Ball, George W. Carnell, Wanwisa Dejnirattisai, Christina Dold, David W Eyre, Philip Hopkins, Alison Howarth, Kreepa Kooblall, Hannah Klim, Susannah Leaver, Lian N Lee, César López-Camacho, Sheila F Lumley, Derek C Macallan, Alexander J. Mentzer, Nicholas M Provine, Jeremy Ratcliff, Jose L. Slon-Campos, Donal T. Skelly, Lucas B. Stolle, Piyada Supasa, Nigel Temperton, Chris Walker, Beibei Wang, Duncan Wyncoll, Peter Simmonds, Teresa Lambe, John Kenneth Ballie, Malcolm G Semple, Peter J. Openshaw, Uri Obolski, Marc Turner, Miles Carroll, Juthathip Mongkolsapaya, Gavin Screaton, Stephen H Kennedy, Lisa M Jarvis, Eleanor Barnes, Susanna Dunachie, José Lourenço, Philippa Matthews, Tihana Bicanic, Paul Klenerman, Sunetra Gupta, Craig P Thompson |
JCI Insight | 2022 |
|
IgG response to SARS-CoV-2 and seasonal coronaviruses contributes to complement overactivation in severe COVID-19 patients
P Castanha, D Tuttle, G Kitsios, J Jacobs, U Braga-Neto, M Duespohl, S Rathod, M Marti, S Wheeler, A Naqvi, B Staines, J Mellors, A Morris, B McVerry, F Shah, C Schaefer, B Macatangay, B Methe, C Fernandez, S Barratt-Boyes, D Burke, E Marques |
The Journal of Infectious Diseases | 2022 |
|
Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada
G Tanunliong, A Liu, S Kaweski, M Irvine, R Reyes, D Purych, M Krajden, M Morshed, I Sekirov, S Gantt, D Skowronski, A Jassem |
Frontiers in immunology | 2022 |
|
Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients
E Garanina, S Hamza, R Stott-Marshall, E Martynova, M Markelova, Y Davidyuk, V Shakirova, N Kaushal, M Baranwal, I Khaertynova, A Rizvanov, T Foster, S Khaiboullina |
Frontiers in microbiology | 2022 |
|
Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals
A Embong, P Nguyen-Contant, J Wang, P Kanagaiah, F Chaves, T Fitzgerald, Q Zhou, G Kosoy, A Branche, B Miller, M Zand, M Sangster, D Topham |
Pathogens | 2022 |
|
A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs
D Pattinson, P Jester, L Guan, S Yamayoshi, S Chiba, R Presler, H Rao, K Iwatsuki-Horimoto, N Ikeda, M Hagihara, T Uchida, K Mitamura, P Halfmann, G Neumann, Y Kawaoka |
Viruses | 2022 |
|
Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks
G Tanunliong, A Liu, R Vijh, T Pidduck, J Kustra, A Márquez, A Choi, M McLennan, A Hayden, C Kearney, S Gantt, M Krajden, M Morshed, A Jassem, I Sekirov |
Frontiers in immunology | 2022 |
|
Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19
W Smit, S van Tol, S van der Wal, F van Vulpen, S la Grouw, L van Lelyveld, G Limonard, A Bossink, G Godeke, S Shrestha, J Reimerink, D Eggink, C Reusken, M Heron, S Thijsen |
Frontiers in immunology | 2022 |
|
COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins
Elko EA, Nelson GA, Mead HL, Kelley EJ, Carvalho ST, Sarbo NG, Harms CE, Le Verche V, Cardoso AA, Ely JL, Boyle AS, Piña A, Henson SN, Rahee F, Keim PS, Celona KR, Yi J, Settles EW, Bota DA, Yu GC, Morris SR, Zaia JA, Ladner JT, Altin JA |
Cell Reports | 2022 |
|
COVID-19 and plasma cells: Is there long-lived protection?
Nguyen DC, Lamothe PA, Woodruff MC, Saini AS, Faliti CE, Sanz I, Lee FE |
Immunological Reviews | 2022 |
|
Distinct Antibody Responses to Endemic Coronaviruses Pre- and Post-SARS-CoV-2 Infection in Kenyan Infants and Mothers
Stoddard CI, Sung K, Ojee E, Adhiambo J, Begnel ER, Slyker J, Gantt S, Matsen FA IV, Kinuthia J, Wamalwa D, Overbaugh J, Lehman DA |
Viruses | 2022 |
|
Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
Hu C, Wang Z, Ren L, Hao Y, Zhu M, Jiang H, Wang S, Li D, Shao Y |
Frontiers in Cellular and Infection Microbiology | 2022 |
|
COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies.
Costa Silva RCM, Bandeira-Melo C, Paula Neto HA, Vale AM, Travassos LH |
Medical Hypotheses | 2022 |
|
Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals
Jaago M, Rähni A, Pupina N, Pihlak A, Sadam H, Tuvikene J, Avarlaid A, Planken A, Planken M, Haring L, Vasar E, Baćević M, Lambert F, Kalso E, Pussinen P, Tienari PJ, Vaheri A, Lindholm D, Timmusk T, Ghaemmaghami AM, Palm K |
Scientific Reports | 2022 |
|
Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19
Herman JD, Atyeo C, Zur Y, Cook CE, Patel NJ, Vanni KM, Kowalski EN, Qian G, Shadick NA, Laffenburger D, Wallace ZS, Sparks JA, Alter G |
2022 | |
|
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Anderson EM, Li SH, Awofolaju M, Eilola T, Goodwin E, Bolton MJ, Gouma S, Manzoni TB, Hicks P, Goel RR, Painter MM, Apostolidis SA, Mathew D, Dunbar D, Fiore D, Brock A, Weaver J, Millar JS, DerOhannessian S, Greenplate AR, Frank I, Rader DJ, Wherry EJ, Bates P, Hensley SE |
Cell Reports | 2022 |
|
Distinct antibody responses to endemic coronaviruses pre- and post-SARS-CoV-2 infection in Kenyan infants and mothers
Stoddard CI, Sung K, Ojee E, Adhiambo J, Begnel ER, Slyker J, Gantt S, Matsen FA IV, Kinuthia J, Wamalwa D, Overbaugh J, Lehman DA |
2022 | |
|
COVID-19 vaccination recruits and matures cross-reactive antibodies to conserved epitopes in endemic coronavirus Spike proteins
Elko EA, Nelson GA, Mead HL, Kelley EJ, Le Verche V, Cardoso AA, Ely JL, Boyle AS, Piña A, Henson SN, Rahee F, Keim PS, Celona KR, Yi J, Settles EW, Yu GC, Morris SR, Zaia JA, Ladner JT, Altin JA |
2022 | |
|
Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases
CT Deakin, GH Cornish, KW Ng, N Faulkner, W Bolland, J Hope, A Rosa, R Harvey, S Hussain, C Earl, BR Jebson, MG Wilkinson, LR Marshall, K OBrien, EC Rosser, A Radziszewska, H Peckham, H Patel, J Heaney, H Rickman, S Paraskevopoulou, CF Houlihan, MJ Spyer, SJ Gamblin, J McCauley, E Nastouli, M Levin, P Cherepanov, C Ciurtin, LR Wedderburn, G Kassiotis |
The American Journal of Medicine | 2021 |
|
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
KW Ng, N Faulkner, AG Wrobel, SJ Gamblin, G Kassiotis |
Seminars in Immunology | 2021 |
|
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response
CY Lin, J Wolf, DC Brice, Y Sun, M Locke, S Cherry, AH Castellaw, M Wehenkel, JC Crawford, VI Zarnitsyna, D Duque, KJ Allison, EK Allen, SA Brown, AH Mandarano, JH Estepp, C Taylor, C Molina-Paris, S Schultz-Cherry, L Tang, PG Thomas, MA McGargill, AH Gaur, JM Hoffman, T Mori, EI Tuomanen, RJ Webby, H Hakim, RT Hayden, DR Hijano, W Awad, R Bajracharya, BL Clark, V Cortez, RH Dallas, T Fabrizio, P Freiden, A Gowen, J Hodges, AM Kirk, EK Roubidoux, RC Mettelman, J Russell-Bell, A Souquette, J Sparks, LA de Velde, A Vazquez-Pagan, K Whitt, TL Wilson, DE Wittman, N Wohlgemuth, G Wu |
Cell Host & Microbe | 2021 |
|
Immunity to SARS‐CoV‐2 induced by infection or vaccination
XC Dopico, S Ols, K Loré, GB Hedestam |
Journal of Internal Medicine | 2021 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)